TS-1

DRUG11 trials

Sponsors

Ehime University Graduate School of Medicine, Taiho Pharmaceutical Co., Ltd., Wyeth is now a wholly owned subsidiary of Pfizer, Hokkaido Gastrointestinal Cancer Study Group, Takara Bio Inc.

Conditions

Advanced Biliary Tract CancerColorectal CancerGastric CancerGastroesophageal Junction AdenocarcinomaHypofractionated RadiotherapyMetastatic Colorectal CancerPancreatic CancerPancreatic Cancer Stage III

Phase 1

Phase I/II Study of Oral S-1 Plus Docetaxel in Elderly Patients With Advanced Gastric Cancer.

SuspendedNCT00209729

Hokkaido Gastrointestinal Cancer Study GroupGastric Cancer

Start: 2005-04-30End: 2010-03-31Target: 50Updated: 2010-05-26

Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer.

Active, not recruitingNCT03252808

Takara Bio Inc.Pancreatic Cancer Stage III, Pancreatic Cancer Stage IV

Start: 2017-09-25End: 2035-03-31Target: 36Updated: 2024-12-09

Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction Adenocarcinoma

RecruitingNCT07182565

West China HospitalGastroesophageal Junction Adenocarcinoma, Hypofractionated Radiotherapy

Start: 2025-11-18End: 2029-08-31Target: 84Updated: 2026-01-06

Phase 2

Phase II Study of Oral S-1 Plus Irinotecan (IRIS) in Patients With Advanced Colorectal Cancer

Hokkaido Gastrointestinal Cancer Study GroupColorectal Cancer

Start: 2004-01-31End: 2007-12-31Updated: 2007-11-01

Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as First Line Chemotherapy in Gastric Cancer (MK-3475-659/KEYNOTE-659)

CompletedNCT03382600

Merck Sharp & Dohme LLCGastric Cancer

Start: 2018-03-26End: 2021-05-30Updated: 2024-06-11

NGS as the First-line Treatment in Advanced Biliary Tract Cancer

CompletedNCT04172402

National Health Research Institutes, TaiwanAdvanced Biliary Tract Cancer

Start: 2019-12-27End: 2024-12-31Updated: 2025-07-22

Phase 3

Randomized Phase III Study of TS-1 Alone Versus TS-1 Plus CDDP in Advanced Gastric Cancer

CompletedNCT00150670

Taiho Pharmaceutical Co., Ltd.Gastric Cancer

Start: 2002-03-31End: 2006-12-31Target: 300Updated: 2011-07-07

Study Evaluating Isovorin in Advanced/Recurrent Gastric Cancer

CompletedNCT00195572

Wyeth is now a wholly owned subsidiary of PfizerGastric Cancer

Start: 2002-05-31End: 2008-08-31Target: 200Updated: 2009-08-13

IRIS Followed by mFOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer

SuspendedNCT00316745

Hokkaido Gastrointestinal Cancer Study GroupMetastatic Colorectal Cancer

Start: 2006-04-30End: 2009-03-31Target: 200Updated: 2007-11-01

Phase III of Gemcitabine Vs TS-1 Vs Gemcitabine Plus TS-1 in Pancreatic Cancer

CompletedNCT00498225

Taiho Pharmaceutical Co., Ltd.Pancreatic Cancer

Start: 2007-07-31End: 2012-06-30Updated: 2012-11-02

Unknown Phase

adjuvant chemotherapy using S-1 in oral squamous cell carcinoma

RecruitingJPRN-UMIN000005164

Ehime University Graduate School of Medicineoral squamous cell carcinoma

Start: 2011-03-01Target: 50Updated: 2026-06-29

Related Papers

Circulating miRNAs as potentially predictive biomarkers for chemoimmunotherapy in advanced biliary tract cancer: a post-hoc analysis of the phase II T1219 study.

2025-08-30

Multicentre, phase II study of gemcitabine and S‐1 in patients with advanced biliary tract cancer: TG1308 study

Liver International2020-05-2810 citations

Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study

European Journal of Cancer2020-03-0962 citations

S-1+oxaliplatin with pembrolizumab for advanced gastric cancer: The cohort 1 in a phase IIb KEYNOTE-659 study.

Journal of Clinical Oncology2020-02-011 citations

Results from phase I study of the oncolytic viral immunotherapy agent canerpaturev (C-REV) in combination with gemcitabine plus nab-paclitaxel for unresectable pancreatic cancer.

Journal of Clinical Oncology2019-01-297 citations

Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer.

2017-02-1625 citations

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

2008-02-201379 citations